Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CAL-120; GS-9820

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calistoga Pharmaceuticals
  • Developer Gilead Sciences
  • Class Purines; Quinazolinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Lymphoma
  • Discontinued Solid tumours

Most Recent Events

  • 03 Dec 2016 Gilead Sciences presented pharmacodynamics and safety data from preclinical studies in Lymphoma and Chronic lymphocytic leukaemia at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH)
  • 01 May 2016 Gilead Sciences completes a phase I trial in Chronic lymphocytic leukaemia and lymphoma in Netherlands (PO) (NCT01705847)
  • 14 May 2014 Gilead Sciences completes enrolment in its phase Ib trial for Lymphoma & Chronic lymphocytic leukaemia in Netherlands (NCT01705847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top